Y-mAbs Therapeutics, Inc.
YMAB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $347 | $298 | $213 | $700 |
| - Cash | $67 | $79 | $106 | $182 |
| + Debt | $1 | $1 | $2 | $4 |
| Enterprise Value | $281 | $220 | $109 | $522 |
| Revenue | $88 | $85 | $65 | $35 |
| % Growth | 3.4% | 30% | 87% | – |
| Gross Profit | $72 | $73 | $58 | $32 |
| % Margin | 82.6% | 86.5% | 88.4% | 92.8% |
| EBITDA | -$31 | -$25 | -$95 | -$54 |
| % Margin | -35% | -29.4% | -145.1% | -156.2% |
| Net Income | -$30 | -$21 | -$96 | -$55 |
| % Margin | -33.8% | -25.3% | -146.4% | -158.4% |
| EPS Diluted | -0.67 | -0.49 | -2.2 | -1.28 |
| % Growth | -36.7% | 77.7% | -71.9% | – |
| Operating Cash Flow | -$16 | -$27 | -$76 | -$103 |
| Capital Expenditures | $0 | $0 | $0 | -$1 |
| Free Cash Flow | -$16 | -$27 | -$76 | -$104 |